Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Portfolio Pulse from
Bolt Biotherapeutics will present data from its Phase 1 dose-escalation clinical study of BDC-3042, a novel immunotherapy targeting dectin-2 in advanced cancer patients, at the AACR Annual Meeting in April 2025. The company will also share preclinical data on two pipeline programs using its Boltbody™ ISAC platform targeting CEA and PD-L1.
March 25, 2025 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Presentation of Phase 1 clinical data for BDC-3042 and preclinical research on Boltbody™ ISACs demonstrates progress in developing novel cancer immunotherapies.
The upcoming presentation of clinical and preclinical data at a major cancer research conference indicates significant scientific progress, which could positively impact investor sentiment and stock performance.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100